Merck & Co. Inc. completed its $2.7 billion acquisition of Burlington, Mass.-based precision medicine specialist ArQule Inc.
The Kenilworth, N.J.-based maker of blockbuster cancer drug Keytruda offered $20 for every ArQule share acquired. At the close of the tender offer period, 75.3% of ArQule's outstanding common stock were validly tendered, with the remaining shares canceled and converted into a right to receive $20 apiece.
ArQule — whose lead product candidate is blood cancer therapy ARQ 531 — will delist from the Nasdaq Global Select Market and operate as a wholly owned subsidiary of Merck.